Combination Immunosuppression in IBD.

Combination Immunosuppression in IBD. Inflamm Bowel Dis. 2018 Feb 15;24(3):539-545 Authors: Bots S, Gecse K, Barclay M, D’Haens G Abstract Whether to use biologic treatment for inflammatory bowel disease as monotherapy or in combination with immunosuppressives has been a matter of debate in the last 2 decades. Combination therapy was not superior in any of the registration trials for Crohn’s disease and ulcerative colitis for TNF antagonists, vedolizumab, or ustekinumab. It needs to be mentioned, though, that none of these trials were powered to detect such differences, and that many…

Read More

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience.

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience. Inflamm Bowel Dis. 2018 Feb 15;24(3):490-501 Authors: Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Safdi M, Popp JW, Langholff W, Sandborn WJ Abstract Background: The purpose of this study was to compare the long-term safety of infliximab and nonbiologic agents as Crohn’s disease (CD) therapy. Methods: Patients with CD were prospectively evaluated in this large, observational registry. Results: Patients (n = 6273) participated in this observational registry from July 1999 through March 2012; 3440 (54.8%) received infliximab (20,971…

Read More

Incorporation of Scribes Into the Inflammatory Bowel Disease Clinic Improves Quality of Care and Physician Productivity.

Incorporation of Scribes Into the Inflammatory Bowel Disease Clinic Improves Quality of Care and Physician Productivity. Inflamm Bowel Dis. 2018 Feb 15;24(3):552-557 Authors: Ewelukwa O, Perez R, Carter LE, Fernandez A, Glover S Abstract Background: Electronic health records (EHRs), despite their positive attributes, increase physician workload and decrease efficiency. The aim of this study was to evaluate the impact of scribes in the Inflammatory Bowel Disease Clinic on improvement of the physician-patient relationship, physician productivity, clinical efficiency, and achievement of some Physician Quality Reporting System (PQRS) metrics. Methods: We analyzed…

Read More

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Full Interchangeability in Regards to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):465-466 Authors: Katsanos KH, Papamichael K, Cheifetz AS, Christodoulou DK PMID: 29462402 [PubMed – in process] PubMed Link: https://www.ncbi.nlm.nih.gov/pubmed/29462402?dopt=Abstract

Read More

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease.

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):471-481 Authors: Han L, Maciejewski M, Brockel C, Afzelius L, Altman RB Abstract Background: Monogenic diseases have been shown to contribute to complex disease risk and may hold new insights into the underlying biological mechanism of Inflammatory Bowel Disease (IBD). Methods: We analyzed Mendelian disease associations with IBD using over 55 million patients from the Optum’s deidentified electronic health records dataset database. Using the significant Mendelian diseases, we performed pathway enrichment analysis and constructed a…

Read More

Duodenal Crohn’s Disease.

Duodenal Crohn’s Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):546-551 Authors: Lightner AL Abstract Symptomatic duodenal Crohn’s disease (CD) is an uncommon disease presentation, especially in isolation. The most common duodenal disease phenotype is stricturing disease rather than inflammatory or perforating. Most patients are asymptomatic and are therefore diagnosed incidentally by cross-sectional imaging or endoscopy. Medical management includes proton pump inhibitor therapy and immunosuppressive therapy including corticosteroids, immunomodulatory therapy, and biologic therapy. Symptomatic strictures can often be treated medically or endoscopically, and do not always require surgery. Surgical options include resection…

Read More

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease.

Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Feb 15;24(3):601-606 Authors: Fiorino G, Ruiz-Argüello MB, Maguregui A, Nagore D, Correale C, Radice S, Gilardi D, Allocca M, Furfaro F, Martínez A, Danese S Abstract Background: Infliximab (IFX) biosimilars CT-P13 and SB2 have comparable efficacy, safety, and immunogenicity to the originator Remicade (RMC). However, concerns about cross-switching patients between the 3 brands were raised in the absence of cross reactivity data between them. We aimed…

Read More

Segmental Resection versus Total Proctocolectomy for Crohn’s Colitis: What is the Best Operation in the Setting of Medically Refractory Disease or Dysplasia?

Segmental Resection versus Total Proctocolectomy for Crohn’s Colitis: What is the Best Operation in the Setting of Medically Refractory Disease or Dysplasia? Inflamm Bowel Dis. 2018 Feb 15;24(3):532-538 Authors: Lightner AL Abstract Crohn’s disease (CD) may affect any part of the gastrointestinal tract. When isolated to the colon, and patients become medically refractory, there are several surgical options – segmental resection, subtotal colectomy with ileorectal anastomosis, or a total proctocolectomy and end ileostomy. Unfortunately, surgery does not cure CD, and, regardless of the extent of bowel removed, recurrence may be…

Read More
<< Go Back